<< Back
Mar 23, 2015

Immune Design Announces Upcoming Financial Results and Immuno-oncology Conference Presentation

SEATTLE and SOUTH SAN FRANCISCO, Calif., March 23, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report fourth quarter and year-end 2014 financial results at the closing of U.S. financial markets on Tuesday, March 31, 2015. Immune Design management will host a webcast and conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 844-831-3023for domestic callers and 920-663-6275for international callers. A live webcast of the call will be available online from the investor relations section of the company website at http://ir.immunedesign.com/events.cfm and will be archived there for ninety days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 11929185.

In addition, Carlos Paya, M.D., Ph.D., President and Chief Executive Officer, will present at the Maidstone Life Sciences 5th Annual Conference "Cancer Immunotherapy" on Thursday, March 26, 2015 at 9:30 am Eastern Time in New York. A live webcast of the presentation will be available online from the investor relations page of the company's corporate website at http://ir.immunedesign.com/events.cfm. After the live webcast, an archive of the presentation will be available on the company website.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. Immune Design's three on-going immuno-oncology clinical programs are the product of its two synergistic discovery platforms, ZVexTM and GLAASTM. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

CONTACT: Media Contact

         Julie Rathbun

         Rathbun Communications




         Investor Contact

         Shari Annes

         Annes Associates